VSIR and non-small cell lung carcinoma: In addition, mAbs targeting fibrinogen-like protein 1 (FGL1), a ligand for Lag-3 for NSCLC, nuclear receptor subfamily 2 group F member 6 (NR2F6), an intracellular IC molecule, and V-set immunoregulatory receptor (VISTA), an immunomodulatory protein expressed in lymphoid organs and bone marrow cells, are now being evaluated in phase I clinical studies for the treatment of solid tumors.1312